Document is current
Any future updates will be listed below
-
Authors
Wilson, Koo
Chiodi, Francesca
Paine, Abby
Hakimi, Zalmai
Ward, Victoria
Macmillan, Tom
Eriksson, Daniel
Mappa, Silvia
-
Funding
Funding for this research was provided by:
Swedish Orphan Biovitrum
ADC Therapeutics
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 4 March 2025
First Online: 28 March 2025
Declarations
:
: Koo Wilson, Zalmai Hakimi, Francesca Chiodi, Silvia Mappa, Daniel Eriksson are employees of Swedish Orphan Biovitrum AB. Abby Paine and Victoria Ward are employees, and Tom Macmillan was an employee of Source Health Economics which received consultancy fees for the systematic literature review and statistical analyses presented in this manuscript. Tom Macmillan is now affiliated with Cytel.
: LOTIS-2 was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonization Good Clinical Practice guidelines, and applicable regulatory requirements. Institutional review boards at participating institutions approved the study protocol and amendments. All patients provided written informed consent.
